# US 2008/0075771 A1 · Hydrophilic opioid abuse deterrent delivery system using opioid antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075771 A1
- Document ID: US20080075771A1
- Status: Published application
- Kind: A1
- Application number: 11/781,050
- Filed: 2007-07-20
- Published: 2008-03-27
- Earliest claimed: 2006-07-21
- Inventors: Jason Vaughn; Michael Crowley; Feng Zhang; John Koleng; Justin Keen; Justin Hughey
- Web page: https://patentgrep.com/patent/US20080075771A1

## CPC

- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/36: Opioid-abuse
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are oral dosage forms of opioid therapeutic agents that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution in aqueous solutions of ethanol are described. The oral dosage forms may include one or more opioid antagonists that are sequestered from the opioid therapeutic agent such that the opioid antagonist has no substantial effect on the activity of the opioid therapeutic agent when the dosage form is taken orally as prescribed, but the opioid antagonist is released in an amount that reduces the effectiveness of the opioid therapeutic agent contained in the dosage form when the dosage form is crushed.

## Claims

### Claim 1

A monolithic solidified oral dosage form prepared by a thermal process comprising an opioid therapeutic agent, an opioid antagonist, and a hydrophilic polymer wherein the oral dosage form releases at least 80% of the therapeutic agent after 2 hours of stirring in a 0.1 N HCl solution and 16 hours stirring in a pH 6.8 phosphate buffer solution using a USP Type II paddle apparatus at 75 rpm and 37° C., and wherein the oral dosage form releases less than 40% of the opioid therapeutic agent after 5 minutes of shaking at 240 cycles/min in a 0.1 N HCl solution followed by 3 hours of shaking on an orbital shaker at 240 cycles/min in an acidic aqueous solution of 40% ethanol at 25° C.; and wherein the opioid antagonist is sequestered from the opioid therapeutic agent such that the opioid antagonist has no substantial effect on the activity of the opioid therapeutic agent when the dosage form is taken orally as prescribed, but the opioid antagonist is released in an amount that reduces the effectiveness of the opioid therapeutic agent contained in the dosage form when the dosage form is crushed.

### Claim 2 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form releases between about 10% and about 50% of the opioid therapeutic agent after 2 hours of stirring in a 0.1 N HCl solution and 1 hour stirring in a pH 6.8 phosphate buffer solution using a USP Type II paddle apparatus at 75 rpm and 37° C.

### Claim 3 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form releases between about 40% and about 70% of the opioid therapeutic agent after 2 hours of stirring in a 0.1 N HCl solution and 10 hours stirring in a pH 6.8 phosphate buffer solution using a USP Type II paddle apparatus at 75 rpm and 37° C.

### Claim 4 (depends on 1)

The oral dosage form of claim 1, wherein the hydrophilic polymer comprises at least 20% by weight of the oral dosage form.

### Claim 5 (depends on 1)

The oral dosage form of claim 1, wherein the hydrophilic polymer comprises one or more hydroxyalkyl celluloses.

### Claim 6 (depends on 1)

The oral dosage form of claim 1, further comprising one or more hydrophobic polymers.

### Claim 7 (depends on 1)

The oral dosage form of claim 1, further comprising one or more acrylic acid based polymers, one or more methacrylic acid based polymers, or mixtures thereof.

### Claim 8 (depends on 1)

The oral dosage form of claim 1, further comprising one or more alkyl celluloses.

### Claim 9 (depends on 1)

The oral dosage form of claim 1, further comprising one or more plasticizers.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The oral dosage form of claim 1, further comprising one or more polycarboxylic acids.

### Claim 12 (depends on 1)

The oral dosage form of claim 1, further comprising one or more α-hydroxy polycarboxylic acids.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The oral dosage form of claim 1, further comprising one or more pore formers.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form has a hardness of at least about 50 kp.

### Claim 20 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form has a diameter of greater than about 5 mm.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form has a moisture content of less than about 5%.

### Claim 24 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is disposed in a capsule.

### Claim 25 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is coated.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is not in the form of an aggregate or composite of individual solid particulates.

### Claim 28 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is not in the form of a compressed tablet.

### Claim 29 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is abuse deterrent.

### Claim 30 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is substantially free of digestible C8-C50 substituted and unsubstituted hydrocarbons.

### Claim 31 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is substantially free of C8-C50 fatty acids, C8-C50 fatty alcohols, glyceryl esters of C8-C50 fatty acids, mineral oils, vegetable oils and waxes.

### Claim 32 (depends on 1)

The oral dosage form of claim 1, wherein the opioid therapeutic agent is substantially uniformly dispersed within the oral dosage form.

### Claim 33

A method of providing an opioid therapeutic agent to a patient comprising providing the patient with a monolithic solidified oral dosage form prepared by a thermal process, the oral dosage form comprising an opioid therapeutic agent, an opioid antagonist, and a hydrophilic polymer, wherein the oral dosage form releases at least 80% of the opioid therapeutic agent after 2 hours of stirring in a 0.1 N HCl solution and 16 hours stirring in a pH 6.8 phosphate buffer solution using a USP Type II paddle apparatus at 75 rpm and 37° C., wherein the oral dosage form releases less than 40% of the opioid therapeutic agent after 5 minutes of shaking at 240 cycles/min in a 0.1 N HCl solution followed by 3 hours of shaking on an orbital shaker at 240 cycles/min in an acidic aqueous solution of 40% ethanol at 25° C., and wherein the opioid antagonist is sequestered from the opioid therapeutic agent such that the opioid antagonist has no substantial effect on the activity of the opioid therapeutic agent when the dosage form is taken orally as prescribed, but the opioid antagonist is released in an amount that reduces the effectiveness of the opioid therapeutic agent contained in the dosage form when the dosage form is crushed.

### Claim at position 34

34-63. (canceled)

### Claim 64

A method of formulating a monolithic solidified oral dosage form, comprising:
forming a mixture of hydrophilic polymer, an opioid therapeutic agent, and an opioid antagonist;
melting the mixture;
permitting the mixture to solidify, wherein the solidified oral dosage releases at least 80% of the opioid therapeutic agent after 2 hours of stirring in a 0.1 N HCl solution and 16 hours stirring in a pH 6.8 phosphate buffer solution using a USP Type II paddle apparatus at 75 rpm and 37° C., wherein the oral dosage form releases less than 40% of the opioid therapeutic agent after 5 minutes of shaking at 240 cycles/min in a 0.1 N HCl solution followed by 3 hours of shaking on an orbital shaker at 240 cycles/min in an acidic aqueous solution of 40% ethanol at 25° C., and wherein the opioid antagonist is sequestered from the opioid therapeutic agent such that the opioid antagonist has no substantial effect on the activity of the opioid therapeutic agent when the dosage form is taken orally as prescribed, but the opioid antagonist is released in an amount that reduces the effectiveness of the opioid therapeutic agent contained in the dosage form when the dosage form is crushed.

### Claim at position 36

65-97. (canceled)
